Open Access

Polymorphisms of α1-antitrypsin and Interleukin-6 genes and the progression of hepatic cirrhosis in patients with a hepatitis C virus infection

T Motawi
T Motawi
, 
OG Shaker
OG Shaker
, 
RM Hussein
RM Hussein
 and 
M Houssen
M Houssen
   | Dec 31, 2016
Balkan Journal of Medical Genetics's Cover Image
About this article
Previous Article
Next Article
Cite
Article Category: Original Article
Published Online: Dec 31, 2016
Page range: 35 - 44
DOI: https://doi.org/10.1515/bjmg-2016-0034
Keywords
© 2016 Motawi T, Shaker OG, Hussein RM, Houssen M
This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

The A1AT and IL-6 genotypes by PCR-RFLP. The left panel shows the M, S and Z alleles of the A1AT genotypes. M: DNA marker; ZZ genotype (179 and 100 bp band); SZ genotype (179, 157, 121 and 100 bp bands); MM genotype (157 and 100 bp bands); SM genotype (157, 121 and 100 bp bands). The right panel shows the G and C alleles of the IL-6 genotypes. GC genotype (168, 119 and 49 bp); GG genotype (168 bp band); CC genotype (119 and 49 bp bands); M: DNA marker.
The A1AT and IL-6 genotypes by PCR-RFLP. The left panel shows the M, S and Z alleles of the A1AT genotypes. M: DNA marker; ZZ genotype (179 and 100 bp band); SZ genotype (179, 157, 121 and 100 bp bands); MM genotype (157 and 100 bp bands); SM genotype (157, 121 and 100 bp bands). The right panel shows the G and C alleles of the IL-6 genotypes. GC genotype (168, 119 and 49 bp); GG genotype (168 bp band); CC genotype (119 and 49 bp bands); M: DNA marker.

The clinical characteristics and biochemical parameters of the control group, chronic hepatitis patients and cirrhotic patients.

ParametersControl (n = 100)Chronic Hepatitis Patients (n= 85)Cirrhotic Patients (n = 65)
SexesM: 45; F: 55M: 55; F: 30M: 35; F: 30
Age (years ± SE)33.10 ± 1.8338.88 ± 1.9238.92 ± 2.36
Serum ALT (IU/mL)30.00 ± 1.3483.53 ± 16.03

significant values (p <0.05) when compared to the control group.

110.00 ± 14.63

significant values (p <0.05) when compared to the control group.

Serum AST (IU/mL)30.20 ± 1.3676.76 ± 11.07

significant values (p <0.05) when compared to the control group.

172.92 ± 27.76

significant values (p <0.05) when compared to the control group.

,

significant values (p <0.05) between chronic hepatitis and cirrhotic patients.

Serum ALP (IU/mL)43.65 ± 1.69113.71 ± 6.51

significant values (p <0.05) when compared to the control group.

119.85 ± 9.49

significant values (p <0.05) when compared to the control group.

Total bilirubin (mg/dL)0.75 ± 0.0450.92 ± 0.0981.09 ± 0.14

significant values (p <0.05) when compared to the control group.

Direct bilirubin (mg/dL)0.15 ± 0.010.25 ± 0.060.28 ± 0.05
Albumin (g/dL)3.85 ± 0.053.69 ± 0.053.21 ± 0.11

significant values (p <0.05) when compared to the control group.

,

significant values (p <0.05) between chronic hepatitis and cirrhotic patients.

Prothrombin time (seconds)11.19 ± 0.1411.53 ± 0.1913.46 ± 0.51

significant values (p <0.05) when compared to the control group.

,

significant values (p <0.05) between chronic hepatitis and cirrhotic patients.

AFP (ng/mL)5.86 ± 0.458.76 ± 0.5527.38 ± 6.91

significant values (p <0.05) when compared to the control group.

,

significant values (p <0.05) between chronic hepatitis and cirrhotic patients.

Fibrosis score (1-6)—1.94 ± 0.184.46 ± 0.14

significant values (p <0.05) when compared to the control group.

The single nucleotide polymorphism pattern of the A1TAT gene in the control group, chronic hepatitis patients and cirrhotic patients.

ParametersControl Group n (%)Chronic Hepatitis Patients n (%)Cirrhotic Patients n (%)
Genotypes:
 MM85 (85.0)40 (47.0)35 (53.8)

significant values (p <0.05) when compared to the control group.

 MS10 (10.0)30 (35.3)15 (23.1)
 MZ5 (5.0)5 (5.9)0 (0.0)
 ZZ0 (0.0)10 (11.8)0 (0.0)
 SS0 (0.00 (0.0)15 (23.1)
Alleles:
 M185 (92.5)115 (67.6)85 (56.4)

significant values (p <0.05) when compared to the control group.

 S10 (5.0)30 (17.6)45 (34.6)

significant values (p <0.05) when compared to the control group.

 Z5 (2.5)25 (14.7)0 (0.0)

The biochemical parameters within different A1AT genotypes in the control group, chronic hepatitis patients and cirrhotic patients.

ParametersControl GroupChronic Hepatitis PatientsCirrhotic Patients
MMMS+MZMMMSMZ+ZZMMMS+SS
Serum ALT (IU/mL)30.2±1.528.7±2.665.4±6.967.7±13.20163.7±80.287.0±80.2176.3±43.4

significant values (p <0.05) when the MS+SS genotypes of cirrhotic patients were compared to the MM genotypes of cirrhotic patients.

Serum AST (IU/mL)30.1±1.631.0±2.568.0±5.657.3±10.50139.0±47.9

significant values (p <0.05) when the MZ+ZZ genotypes of chronic hepatitis patients were compared to the MM genotypes of chronic hepatitis patients.

significant values (p <0.05) when the MZ+ZZ genotypes of chronic hepatitis patients were compared to the MS genotypes of chronic hepatitis patients.

127.7±20.1300.7±65.9

significant values (p <0.05) when the MS+SS genotypes of cirrhotic patients were compared to the MM genotypes of cirrhotic patients.

Serum ALP (IU/mL)44.5±1.938.7±0.9109.3±7.4115.5±5.70122.0±34.5114.6±10.8130.7±34.8
Total bilirubin (mg/dL)0.8±0.10.7±0.20.8±0.070.9±0.101.3±0.50.9±0.11.8±0.4

significant values (p <0.05) when the MS+SS genotypes of cirrhotic patients were compared to the MM genotypes of cirrhotic patients.

Direct bilirubin (mg/dL)0.2±0.020.1±0.030.2±0.020.2±0.040.5±0.30.2±0.010.5±0.2

significant values (p <0.05) when the MS+SS genotypes of cirrhotic patients were compared to the MM genotypes of cirrhotic patients.

Albumin (g/dL)3.8±0.053.9±0.23.7±0.13.7±0.103.6±0.033.3±0.12.7±0.1

significant values (p <0.05) when the MS+SS genotypes of cirrhotic patients were compared to the MM genotypes of cirrhotic patients.

Prothrombin time (seconds)11.2±0.211.3±0.311.5±0.211.2±0.2012.3±0.913.7±0.615.0±0.6
AFP (ng/mL)6.0±0.55.0±1.08.6±0.98.7±1.009.3±1.025.6±10.348.3±11.2
Fibrosis score (1-6)——2.1±0.31.5±0.202.3±0.34.6±0.24.3±0.3

The single nucleotide polymorphism pattern of the IL-6 gene in the control group, chronic hepatitis patients and cirrhotic patients.

ParametersControl Group n (%)Chronic Hepatitis Patients n (%)Cirrhotic Patients n (%)
Genotypes:
 GG100 (100.0)60 (70.6)40 (61.5)

significant values (p <0.05) when compared to the control group.

 GC0 (0.0)20 (23.5)25 (38.5)
 CC0 (0.0)5 (5.9)0 (0.0)
Alleles:
 G200 (100.0)140 (82.4)105 (80.8)
 C0 (0.0)30 (17.6)25 (19.2)

significant values (p <0.05) when compared to the control group.

The biochemical parameters within different IL-6 genotypes in the control group, chronic hepatitis patients and cirrhotic patients.

ParametersGenotypes
Control GroupChronic Hepatitis PatientsCirrhotic Patients
GGGG+GCCCGGGC
Serum ALT (IU/mL)30.00±1.3480.75±7.09128.10±52.91102.63±17.87121.80±26.81
Serum AST (IU/mL)30.20±1.3673.33±5.61137.45±35.74150.50±28.65208.80±54.69
Serum ALP (IU/mL)43.65±1.69115.93±5.4578.34±19.49125.25±14.21111.20±10.31
Total bilirubin (mg/dL)0.75±0.0450.92±0.060.90±0.321.09±0.171.00±0.28
Direct bilirubin (mg/dL)0.15±0.010.26±0.020.20±0.190.29±0.070.26±0.09
Albumin (g/dL)3.85±0.053.69±0.073.60±0.063.26±0.133.12±0.23
Prothrombin time (seconds)11.19±0.1411.50±0.1512.10±0.5814.00±0.6312.60±0.81
AFP (ng/mL)5.86±0.458.87±0.657.00±1.0525.63±8.9430.20±12.04
Fibrosis score (1-6)—1.93±0.232.00±0.324.50±0.194.40±0.24
eISSN:
1311-0160
Language:
English
Publication timeframe:
2 times per year
Journal Subjects:
Medicine, Basic Medical Science, other
Journal RSS Feed